Upadacitinib, as a tablet and oral solution, is now FDA approved to treat children age 2 years and older with active polyarticular juvenile idiopathic arthritis or psoriatic arthritis.
Search results for: cardiovascular disease
Coagulation Education: Treatment Options for Antiphospholipid Syndrome
Dr. Maria Tektonidou discussed the latest recommendations for the treatment of patients with antiphospholipid syndrome (APS), including obstetric and thrombotic subtypes.
The Impact of Climate Change
Although research is still emerging, evidence suggests changes in climate, such as increases in heat, pollution and allergens, may increase the risk of flare and hospitalization in patients with rheumatoid arthritis, systemic lupus erythematosus and other rheumatic conditions. Paul Dellaripa, MD, discussed the research and how rheumatologists can help their patients.
What’s New in Treatment: IgA Vasculitis & IgA Nephropathy
Dr. Jens Thiel provided a detailed overview of specific treatments for patients with immunoglobulin A (IgA) vasculitis and IgA nephropathy, highlighting treatments in early clinical trials.
Tofacitinib Increases Risk of Venous Thromboembolism
Background & Objectives The ORAL Surveillance trial (NCT02092467), a postauthorization safety study of tofacitinib in patients with rheumatoid arthritis (RA) aged 50 years or older with at least one additional cardiovascular risk factor, found a dose-dependent increase in venous thromboembolism (VTE) and pulmonary embolism (PE) events when patients were treated with tofacitinib vs. a tumor…
Dual Certification: Med-Peds Rheumatology Is a Small, but Growing, Specialty
Wondering how best to care for an adult patient with juvenile idiopathic arthritis-associated uveitis or a pediatric patient with early-onset osteoarthritis? Unsure how to manage a 23-year-old with chronic nonbacterial osteomyelitis or an 8-year-old with tophaceous gout due to Lesch-Nyhan syndrome? Ask a Med-Peds rheumatologist. What Is a Med-Peds Rheumatologist? Med-Peds rheumatologists in the U.S….
3 AC&R Study Summaries: Prescribing Patterns, PMR & Glucocorticoids, & Infection Screening
A Shift in Prescribing Patterns Safety issues prompt discontinuation of tofacitinib By Stephanie Song, MD, & Joshua F. Baker, MD, MSCE Why was this study done? The ORAL Surveillance study highlighted risks of cardiac events, thromboembolism (VTE) and malignancy associated with use of Janus kinase inhibitors (JAKi). We sought to determine the impact of safety…
When a JAK Inhibitor Fails
What Are the Therapeutic Alternatives When a Janus Kinase Inhibitor Fails to Work? SAN DIEGO—Treatment alternatives after Janus kinase (JAK) inhibitor failure in real-life conditions were analyzed and presented at ACR Convergence 2023 by Pablo Francisco Muñoz Martínez, a rheumatologist at the Hospital Universitario y Politécnico La Fe, Sagunto, Spain.1 JAK inhibitors are newer, targeted…
Pharmacokinetic Modeling & Efficacy Extrapolation: FDA Takes New Approaches to Drug Approvals
An array of new and expanded indications of therapeutics for rheumatic disease last year relied on pharmacokinetic modeling for intravenous dosing and efficacy extrapolation for pediatric populations.
Can SGLT2 Inhibitors Protect Our SLE Patients?
SAN DIEGO—At ACR Convergence 2023, Plenary Session 2, April M. Jorge, MD, shared data concerning the potential cardio- and renal-protective benefits of sodium-glucose co-transporter-2 inhibitors in patients with systemic lupus erythematosus and lupus nephritis.
- « Previous Page
- 1
- …
- 37
- 38
- 39
- 40
- 41
- …
- 65
- Next Page »